Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$150.32M+708.05%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc Stapley
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 755
- Beta
- 1.93
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 22.94
Financials
Revenue
$150.32M+708.0%Net Income
$25.49MEBITDA
$24.28MFree Cash Flow
$42.97MEPS (diluted)
$0.31Shares Outstanding (diluted)
82.23M+194.5%Operating Expenses
$85.15MCash & Debt
$485.23MReturn of Capital
$4.29MRevenue by Segment (annual)
$517.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $517.14M | $66.35M | $0.84 |
| 2024 | $445.76M | $24.14M | $0.32 |
| 2023 | $361.05M | $-74.40M | $-1.02 |
| 2022 | $296.54M | $-36.56M | $-0.51 |
| 2021 | $219.51M | $-75.56M | $-1.11 |
| 2020 | $117.48M | $-34.91M | $-0.66 |
| 2019 | $120.37M | $-12.60M | $-0.27 |
| 2018 | $92.01M | $-23.00M | $-0.62 |
| 2017 | $71.95M | $-31.00M | $-0.91 |
| 2016 | $65.08M | $-31.36M | $-1.09 |
| 2015 | $49.50M | $-33.70M | $-1.30 |
| 2014 | $38.19M | $-29.37M | $-1.36 |
| 2013 | $21.88M | $-25.58M | $-6.15 |
| 2012 | $11.63M | $-18.65M | $-1.31 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.24
- Implied price
- $62.03
- Return from $45.81
- 6.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.84 — -32.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 34 | 42 | 50 | 58 | 66 |
|---|---|---|---|---|---|
| -2.0% | -10.7% | -6.9% | -3.6% | -0.7% | 1.9% |
| 3.0% | -6.2% | -2.1% | 1.3% | 4.4% | 7.1% |
| 8.0% | -1.6% | 2.6% | 6.3% | 9.5% | 12.3% |
| 13.0% | 2.9% | 7.4% | 11.2% | 14.5% | 17.5% |
| 18.0% | 7.5% | 12.1% | 16.1% | 19.6% | 22.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·7d ago·Negative
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
View source ↗ - Newsglobenewswire.com·10d ago·Negative
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification
View source ↗ - Newszacks.com·10d ago·Positive
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
View source ↗ - Newsgurufocus.com·26d ago·Neutral
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
View source ↗ - Newszacks.com·40d ago·Neutral
Is it Worth Adding Veracyte Stock to Your Portfolio Now? VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
View source ↗ - Newszacks.com·41d ago·Neutral
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity? Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
View source ↗ - Newszacks.com·49d ago·Neutral
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsseekingalpha.com·57d ago·Positive
Veracyte: Diagnostics With Favorable Economics Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
View source ↗ - Newsseekingalpha.com·57d ago·Neutral
Veracyte: Core Growth Funds Prosigna And TrueMRD Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core gr
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.43 per share
Typical surprise +41.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.54 vs $0.41beat
- Tue, May 5$0.52 vs $0.34beat
- Wed, Feb 25$0.53 vs $0.41beat
- Tue, Nov 4$0.51 vs $0.32beat
- Wed, Aug 6$0.44 vs $0.31beat
- Wed, May 7$0.31 vs $0.12beat
Estimates and results for VCYT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VCYT officers and directors.
- Bought
- —
- Sold
- $17.0m
0 trades
40 trades
- Leite Johnsold
- Holstein Jenssold
- Febbo Phillip G.sold
- Febbo Phillip G.sold
- Chambers Rebeccasold
- Chambers Rebeccasold
- Mcguire Anniesold
- Mcguire Anniesold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2026 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (33d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 11, 2025 (25d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (32d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (30d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 5, 2020 (7d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 18, 2020 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 10, 2020 (17d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 10, 2020 (29d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (31d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.